Massive Bio Virtual Tumor Board (VTB) identified clinical trials for 80% of these heavily treated patients, and 50% of patients decided to pursue a clinical trial. VTB resulted in data that impacted clinical decisions in 100% of cases. VTB achieved 88% cost reduction compared to standard therapies due to clinical trial enrolment (517,000USD vs 61,000USD). Treatment options as prioritised by VTB also provided an estimated reported PFS advantage (6.3 months) compared to standard therapy (3.6 months).
Article in Annals of Oncology was ranked at top 7
Massive Bio has onboarded over 160,000+ cancer patients to find their clinical trial
